{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:46:50Z","timestamp":1760784410102,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00520-018-4074-8","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T01:48:20Z","timestamp":1517881700000},"page":"2323-2331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Filgrastim use in patients receiving chemotherapy for early-stage breast cancer\u2014a survey of physicians and patients"],"prefix":"10.1007","volume":"26","author":[{"given":"John","family":"Hilton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Vandermeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Sienkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasha","family":"Mazzarello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Stober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Fergusson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Blanchette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil A.","family":"Joy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Brianne Bota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0738-2713","authenticated-orcid":false,"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"key":"4074_CR1","unstructured":"Granulocyte-colony stimulating factors or antibiotics for primary prophylaxis for febrile neutropenia. In: Editor (ed)^(eds) Book Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia. https:\/\/ClinicalTrials.gov\/show\/NCT02816112 , City"},{"key":"4074_CR2","unstructured":"A Study to compare administration schedules of G-CSF (filgrastim) for primary prophylaxis of febrile neutropenia. In: Editor (ed) (eds) Book A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia. https:\/\/ClinicalTrials.gov\/show\/NCT02816164 , City"},{"key":"4074_CR3","unstructured":"(2016) Cancer Care Ontario GCSF Recommendations 2016"},{"key":"4074_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for R, Treatment of C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332","journal-title":"Eur J Cancer"},{"key":"4074_CR5","unstructured":"Collins D (2017) What could drive Amgen's growth in 2017. wwwmarketrealistcom http:\/\/marketrealist.com\/2017\/05\/what-could-drive-amgens-growth-in-2017\/ : Accessed 9 November 2017"},{"issue":"Suppl 5","key":"4074_CR6","doi-asserted-by":"publisher","first-page":"v252","DOI":"10.1093\/annonc\/mdq196","volume":"21","author":"J Naurois de","year":"2010","unstructured":"de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F, Group EGW (2010) Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 21(Suppl 5):v252\u2013v256. https:\/\/doi.org\/10.1093\/annonc\/mdq196","journal-title":"Ann Oncol"},{"issue":"1","key":"4074_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clgc.2016.07.018","volume":"15","author":"R Fernandes","year":"2017","unstructured":"Fernandes R, Mazzarello S, Hutton B, Shorr R, Ibrahim MF, Jacobs C, Ong M, Clemons M (2017) A systematic review of the incidence and risk factors for taxane acute pain syndrome in patients receiving taxane-based chemotherapy for prostate cancer. Clin Genitourin Cancer 15(1):1\u20136. https:\/\/doi.org\/10.1016\/j.clgc.2016.07.018","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"4074_CR8","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00520-015-2941-0","volume":"24","author":"R Fernandes","year":"2016","unstructured":"Fernandes R, Mazzarello S, Majeed H, Smith S, Shorr R, Hutton B, Ibrahim MF, Jacobs C, Ong M, Clemons M (2016) Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy-a systematic review. Support Care Cancer 24(4):1583\u20131594. https:\/\/doi.org\/10.1007\/s00520-015-2941-0","journal-title":"Support Care Cancer"},{"issue":"1","key":"4074_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-016-4028-0","volume":"161","author":"R Fernandes","year":"2017","unstructured":"Fernandes R, Mazzarello S, Stober C, Vandermeer L, Dudani S, Ibrahim MF, Majeed H, Perdrizet K, Shorr R, Hutton B, Fergusson D, Clemons M (2017) Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review. Breast Cancer Res Treat 161(1):1\u201310. https:\/\/doi.org\/10.1007\/s10549-016-4028-0","journal-title":"Breast Cancer Res Treat"},{"key":"4074_CR10","unstructured":"Inc AC (2016) Neulasta (pegfilgrastim) injection, for subcutaneous use In: Editor (ed)^(eds) Book Neulasta (pegfilgrastim) injection, for subcutaneous use City"},{"key":"4074_CR11","unstructured":"Inc AC (2016) Product Monograph (filgrastim). Version Oct 2016. In: Editor (ed)^(eds) Book Product Monograph (filgrastim). Version Oct 2016., City"},{"issue":"6","key":"4074_CR12","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00520-017-3580-4","volume":"25","author":"C Jacobs","year":"2017","unstructured":"Jacobs C, Clemons M, Mazzarello S, Hutton B, Joy AA, Brackstone M, Freedman O, Vandermeer L, Ibrahim M, Fergusson D, Hilton J (2017) Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients. Support Care Cancer 25(6):1881\u20131886. https:\/\/doi.org\/10.1007\/s00520-017-3580-4","journal-title":"Support Care Cancer"},{"issue":"11","key":"4074_CR13","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00520-015-2731-8","volume":"23","author":"C Jacobs","year":"2015","unstructured":"Jacobs C, Hutton B, Mazzarello S, Smith S, Joy A, Amir E, Ibrahim MF, Gregario N, Daigle K, Eggert L, Clemons M (2015) Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients. Support Care Cancer 23(11):3269\u20133275. https:\/\/doi.org\/10.1007\/s00520-015-2731-8","journal-title":"Support Care Cancer"},{"issue":"4","key":"4074_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/jep.12379","volume":"21","author":"C Jacobs","year":"2015","unstructured":"Jacobs C, Ibrahim MF, Clemons M, Hutton B, Simos D, Caudrelier JM, Graham ID, Smith S, Addison C, Arnaout A (2015) Treatment choices for patients with invasive lobular breast cancer: a doctor survey. J Eval Clin Pract 21(4):740\u2013748. https:\/\/doi.org\/10.1111\/jep.12379","journal-title":"J Eval Clin Pract"},{"issue":"34","key":"4074_CR15","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","volume":"24","author":"SE Jones","year":"2006","unstructured":"Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24(34):5381\u20135387. https:\/\/doi.org\/10.1200\/JCO.2006.06.5391","journal-title":"J Clin Oncol"},{"key":"4074_CR16","unstructured":"Network NCC NCCN Clinical practice guidelines in oncology: myeloid growth factors, version 1.2010. In: Editor (ed)^(eds) Book NCCN clinical practice guidelines in oncology: myeloid growth factors, version 1.2010, City"},{"key":"4074_CR17","unstructured":"Programs OPD (2016) Grastofil (filgrastim) frequently asked questions. Ministry of Health and Long-Term Care http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/opdp_eo\/notices\/fq_exec_office_20161221.pdf : Accessed September 9, 2017"},{"key":"4074_CR18","first-page":"CD007913","volume":"10","author":"P Renner","year":"2012","unstructured":"Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M (2012) Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev 10:CD007913","journal-title":"Cochrane Database Syst Rev"},{"key":"4074_CR19","doi-asserted-by":"crossref","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO, American Society of Clinical O (2015) Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update J Clin Oncol 33: 3199\u20133212","DOI":"10.1200\/JCO.2015.62.3488"},{"issue":"19","key":"4074_CR20","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19):3187\u20133205. https:\/\/doi.org\/10.1200\/JCO.2006.06.4451","journal-title":"J Clin Oncol"},{"key":"4074_CR21","unstructured":"Warwick G, Lungu, E (2017) Potential Savings from Biosimilars Canada. Patented Medicine Prices Review Board https:\/\/www.cadth.ca\/sites\/default\/files\/symp-2017\/presentations\/april24-2017\/Concurrent-Session-B4-Gary-Warwick.pdf Accessed 9 September, 2017"},{"issue":"4","key":"4074_CR22","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.3747\/co.19.948","volume":"19","author":"X Zhu","year":"2012","unstructured":"Zhu X, Bouganim N, Vandermeer L, Dent SF, Dranitsaris G, Clemons MJ (2012) Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience. Curr Oncol 19(4):e239\u2013e243. https:\/\/doi.org\/10.3747\/co.19.948","journal-title":"Curr Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4074-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4074-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4074-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T05:40:23Z","timestamp":1570686023000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4074-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["4074"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4074-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2018,2,6]]},"assertion":[{"value":"9 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}